The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
暂无分享,去创建一个
Julie Kreyenbuhl | Deanna L Kelly | D. Kelly | D. Boggs | R. Buchanan | J. Kreyenbuhl | S. Himelhoch | Robert W Buchanan | E. Peterson | Jason M Noel | Douglas L Boggs | Bernard A Fischer | Seth Himelhoch | Beverly Fang | Eunice Peterson | Patrick R Aquino | William Keller | B. Fischer | Patrick R. Aquino | Beverly Fang | Jason Noel | William R. Keller
[1] John Battaglia,et al. Pharmacological Management of Acute Agitation , 2012, Drugs.
[2] F. Dickerson,et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.
[3] F. Dickerson,et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. , 2010, Schizophrenia bulletin.
[4] John M. Davis,et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.
[5] R. Rosenheck,et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. , 2008, The Journal of clinical psychiatry.
[6] Ann E. Maloney,et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. , 2008, The American journal of psychiatry.
[7] Jeffrey A. Lieberman,et al. Extrapyramidal side-effects of antipsychotics in a randomised trial , 2008, British Journal of Psychiatry.
[8] E. Stip,et al. Should We Treat Auditory Hallucinations with Repetitive Transcranial Magnetic Stimulation? A Metaanalysis , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[9] Richard A. Van Dorn,et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia , 2008, British Journal of Psychiatry.
[10] P. Jatlow,et al. A Placebo-Controlled Trial of Bupropion Combined with Nicotine Patch for Smoking Cessation in Schizophrenia , 2008, Biological Psychiatry.
[11] T. d'Amato,et al. Maintenance treatment with transcranial magnetic stimulation in a patient with late-onset schizophrenia. , 2008, The American journal of psychiatry.
[12] L. Hranov,et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.
[13] S. Kumra,et al. Clozapine and “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison , 2008, Biological Psychiatry.
[14] B. Bharadwaj,et al. Successful use of maintenance rTMS for 8 months in a patient with antipsychotic-refractory auditory hallucinations , 2008, Schizophrenia Research.
[15] W. Bobo,et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. , 2008, The Journal of clinical psychiatry.
[16] S. Marder,et al. Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study , 2007, Biological Psychiatry.
[17] L. Citrome. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. , 2007, The Journal of clinical psychiatry.
[18] J. McEvoy,et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. , 2007, Journal of psychiatric research.
[19] H. Möller,et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. , 2007, The Journal of clinical psychiatry.
[20] D. Goff,et al. A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia , 2007, Journal of clinical psychopharmacology.
[21] J. Lieberman,et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.
[22] R. Emsley,et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study , 2007, Schizophrenia Research.
[23] R. Kahn,et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.
[24] G. Currier,et al. Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations , 2007, Journal of psychiatric practice.
[25] André Aleman,et al. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. , 2007, The Journal of clinical psychiatry.
[26] Alexander L. Miller,et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. , 2007, The American journal of psychiatry.
[27] P. Lim,et al. Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study , 2007, Journal of clinical psychopharmacology.
[28] P. Lim,et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial , 2007, Schizophrenia Research.
[29] D. Sack,et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. , 2007, The Journal of clinical psychiatry.
[30] Young-Chul Chung,et al. Second run of transcranial magnetic stimulation has no effects on persistent auditory hallucinations , 2007, World Journal of Biological Psychiatry.
[31] Sergio P. Rigonatti,et al. Effects of Repetitive Transcranial Magnetic Stimulation on Auditory Hallucinations Refractory to Clozapine , 2006, The Journal of clinical psychiatry.
[32] Alexander L. Miller,et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. , 2004, The Journal of clinical psychiatry.
[33] P. Haddad,et al. Adverse Effects of Atypical Antipsychotics , 2007, CNS drugs.
[34] D. Wiersma,et al. Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome , 2007 .
[35] D. Robinson,et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. , 2006, The American journal of psychiatry.
[36] A. Baker,et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. , 2006, The American journal of psychiatry.
[37] Peter B. Jones,et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.
[38] D. Oren,et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol , 2006, Psychopharmacology.
[39] J. Lieberman,et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. , 2006, The American journal of psychiatry.
[40] R. Mcquade,et al. The Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients with Acute Exacerbation of Schizophrenia , 2006, CNS Spectrums.
[41] J. Lieberman,et al. Olanzapine and haloperidol in first episode psychosis: Two-year data , 2006, Schizophrenia Research.
[42] G. Simpson,et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. , 2006, The Journal of clinical psychiatry.
[43] Alexander L. Miller,et al. Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial , 2006 .
[44] Alexander L. Miller,et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. , 2006, Psychiatric services.
[45] R. Kongsakon,et al. Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[46] J. Newcomer,et al. The Metabolic Effects of Antipsychotic Medications , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[47] J. Rapoport,et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. , 2006, Archives of General Psychiatry.
[48] P. Czobor,et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. , 2006, Archives of general psychiatry.
[49] J. Lieberman,et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.
[50] J. Daléry,et al. Is rTMS efficient as a maintenance treatment for auditory verbal hallucinations? A case report , 2006, Schizophrenia Research.
[51] P. Fitzgerald,et al. The treatment of recurring auditory hallucinations in schizophrenia with rTMS , 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[52] Peter B. Jones,et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. , 2005, Schizophrenia bulletin.
[53] M. Lambert,et al. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. , 2005, The international journal of neuropsychopharmacology.
[54] E. Vicaut,et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. , 2005, Journal of psychiatric research.
[55] L. Kennedy. Effectiveness of Antipsychotic Drugs in Patients With Chronic SchizophreniaLieberman JA, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (Columbia Univ, New York; et al) N Engl J Med 353:1209–1223, 2005§ , 2006 .
[56] C. Morganti,et al. Aripiprazole for schizophrenia. , 2006, The Cochrane database of systematic reviews.
[57] P. Czobor,et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. , 2005, The Journal of clinical psychiatry.
[58] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[59] J. Finsterer,et al. Antipsychotic drugs and QT prolongation. , 2005, International clinical psychopharmacology.
[60] S. Soumerai,et al. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. , 2005, The British journal of psychiatry : the journal of mental science.
[61] R. Bella,et al. Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations , 2005, Neuroscience Letters.
[62] D. Hatsukami,et al. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia , 2005, Schizophrenia Research.
[63] John H. Krystal,et al. Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample , 2005, Biological Psychiatry.
[64] D. Goff,et al. A Double-blind Placebo-Controlled Trial of Bupropion Sustained-Release for Smoking Cessation in Schizophrenia , 2005, Journal of clinical psychopharmacology.
[65] Philip D. Harvey,et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. , 2005, The American journal of psychiatry.
[66] J. Modestin,et al. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. , 2005, The Journal of clinical psychiatry.
[67] R. Baldessarini,et al. Suicidal risk during treatment with clozapine: a meta-analysis , 2005, Schizophrenia Research.
[68] P. Chue,et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets , 2005, European Neuropsychopharmacology.
[69] J. Daléry,et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia , 2005, Biological Psychiatry.
[70] J. Newcomer. Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.
[71] R. Conley,et al. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. , 2005, Drugs.
[72] S. Laurent,et al. Arterial Stiffness and Stroke in Hypertension , 2005, CNS drugs.
[73] Alexander L. Miller,et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. , 2007, The Journal of clinical psychiatry.
[74] C. Kelly,et al. Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning , 2004, European Journal of Clinical Pharmacology.
[75] A. Schreiner,et al. Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis , 2004, International clinical psychopharmacology.
[76] P. Buckley. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials , 2004, Current medical research and opinion.
[77] Klaus P. Ebmeier,et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia , 2004, Psychiatry Research.
[78] B. Kinon,et al. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. , 2004, The American journal of emergency medicine.
[79] J. Lieberman,et al. Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol , 2004, Journal of clinical psychopharmacology.
[80] D. Goff,et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. , 2004, The Journal of clinical psychiatry.
[81] R. Anziano,et al. A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition , 2004, Journal of clinical psychopharmacology.
[82] Julie Kreyenbuhl,et al. Practice guideline for the treatment of patients with schizophrenia , 1997 .
[83] I. Bitter,et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[84] F. Dickerson,et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. , 2004, Schizophrenia bulletin.
[85] G. Bartzokis,et al. Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia , 2004 .
[86] H. Ascher-Svanum,et al. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting. , 2004, The American journal of managed care.
[87] D. Charney,et al. Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.
[88] G. Tollefson,et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse , 2003, Journal of clinical psychopharmacology.
[89] R. Conley,et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. , 2003, Journal of clinical psychopharmacology.
[90] June Corwin,et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. , 2003, JAMA.
[91] G. Simpson,et al. Psychopharmacology: underuse of evidence-based treatments in psychiatry. , 2003, Psychiatric services.
[92] T. Pigott,et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. , 2003, The Journal of clinical psychiatry.
[93] R. Baker,et al. Effectiveness of Rapid Initial Dose Escalation of up to Forty Milligrams per Day of Oral Olanzapine in Acute Agitation , 2003, Journal of clinical psychopharmacology.
[94] J. Lieberman,et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. , 2003, The American journal of psychiatry.
[95] R. Liberman,et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. , 2003, The American journal of psychiatry.
[96] S. Potkin,et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.
[97] S. Keith,et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. , 2003, The American journal of psychiatry.
[98] J. Gold,et al. Olanzapine treatment of residual positive and negative symptoms , 2003, Schizophrenia Research.
[99] J. Lieberman,et al. Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine , 2003, Neuropsychopharmacology.
[100] Alan I Green,et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). , 2003, Archives of general psychiatry.
[101] K. Chou,et al. The Impact of Smoking Cessation Programs on Smoking-Related Health Belief and Rate of Quit-Smoking among Schizophrenic Patients , 2002 .
[102] J. Kane,et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.
[103] H. Meltzer,et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study , 2002, International clinical psychopharmacology.
[104] T. George,et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia , 2002, Biological Psychiatry.
[105] R. Palmer,et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. , 2002, Archives of general psychiatry.
[106] R. Conley,et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. , 2002, The American journal of psychiatry.
[107] J. Csernansky,et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. , 2002, The New England journal of medicine.
[108] W. Gaebel,et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies , 2002, Schizophrenia Research.
[109] P. Hoffmann,et al. Investigation of the Potential of Clozapine to Cause Torsade de Pointes , 2002, Adverse drug reactions and toxicological reviews.
[110] J. Lieberman,et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. , 2001, Psychiatric services.
[111] Evins,et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. , 2001, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[112] M. Kotler,et al. Association of autonomic dysfunction and clozapine , 2001, British Journal of Psychiatry.
[113] R. Emsley,et al. Determining the optimal dose of haloperidol in first-episode psychosis , 2001, Journal of psychopharmacology.
[114] L. San,et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. , 2001, The American journal of psychiatry.
[115] R. Rosenheck,et al. Impact of clozapine on completed suicide. , 2001, The American journal of psychiatry.
[116] S. Potkin,et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial , 2001, Psychopharmacology.
[117] J. Zajecka,et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. , 2001, The Journal of clinical psychiatry.
[118] D. Ziedonis,et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. , 2000, The American journal of psychiatry.
[119] G. Cassano,et al. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. , 2000, The Journal of clinical psychiatry.
[120] J. Kwon,et al. Electrocardiographic abnormalities in patients treated with clozapine. , 2000, The Journal of clinical psychiatry.
[121] S. Ayis,et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.
[122] Abraham Weizman,et al. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. , 1999, The American journal of psychiatry.
[123] R. Emsley,et al. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. , 1999, Schizophrenia bulletin.
[124] W. Reid,et al. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. , 1998, Psychiatric services.
[125] Abraham Weizman,et al. Diminished Suicidal and Aggressive Behavior, High Plasma Norepinephrine Levels, and Serum Triglyceride Levels in Chronic Neuroleptic‐Resistant Schizophrenic Patients Maintained on Clozapine , 1998, Clinical neuropharmacology.
[126] D M Steinwachs,et al. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. , 1998, Schizophrenia bulletin.
[127] D M Steinwachs,et al. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. , 1998, Schizophrenia bulletin.
[128] W. Dubin,et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. , 1997, The American journal of emergency medicine.
[129] G. Simpson,et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting , 1997, International clinical psychopharmacology.
[130] K. Rothman,et al. Mortality in current and former users of clozapine , 1996, Schizophrenia Research.
[131] J. McEvoy,et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. , 1996, The American journal of psychiatry.
[132] J. Lieberman,et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. , 1995, The American journal of psychiatry.
[133] H. Meltzer,et al. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. , 1995, The American journal of psychiatry.
[134] L. Dixon,et al. Conventional antipsychotic medications for schizophrenia. , 1995, Schizophrenia bulletin.
[135] S. Potkin,et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. , 1994, The Journal of clinical psychiatry.
[136] H. Meltzer,et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. , 1993, Journal of clinical psychopharmacology.
[137] H. Ring,et al. Rapid Tranquillisation , 1992, British Journal of Psychiatry.
[138] E. Miyawaki,et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. , 1991, The Journal of clinical psychiatry.
[139] R. Cadoret,et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. , 1991, The American journal of psychiatry.
[140] J. Bodkin. Emerging uses for high-potency benzodiazepines in psychotic disorders. , 1990, The Journal of clinical psychiatry.
[141] A. Green,et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. , 1986, Psychosomatics.